Skip to main
NAGE

ChromaDex Corp (NAGE) Stock Forecast & Price Target

ChromaDex Corp (NAGE) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Niagen Bioscience is a unique company in the health and wellness space, with a strong focus on NAD+ science and a robust portfolio of over 100 patents. The company's flagship product, Tru Niagen, has been clinically proven to increase NAD+ levels and has potential for broad use in both the supplement and pharmaceutical markets. Additionally, the company's recent expansion into the skincare market and its plans to introduce a pen-like autoinjector and other innovative products highlight its strong potential for growth. While risks such as slower sales growth and potential legal issues exist, the company's recent lawsuit against regulators could provide a long-term tailwind. With a solid financial standing, including strong projected cash on hand and moderate revenue outperformance, Niagen Bioscience has the potential for continued success in the rapidly growing health and wellness market.

Bears say

Niagen Bioscience is a leader in the NAD+ science and healthy-aging industry, but they face challenges in maintaining sales growth and financial stability. The company's reliance on their Tru Niagen brand and ongoing lawsuits and negative studies in regards to their products could hurt their reputation and sales. Furthermore, the highly competitive nature of the health and wellness market, potential regulatory changes, and stock dilution risk could also negatively impact the company's financial outlook.

ChromaDex Corp (NAGE) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ChromaDex Corp (NAGE) Forecast

Analysts have given ChromaDex Corp (NAGE) a Strong Buy based on their latest research and market trends.

According to 2 analysts, ChromaDex Corp (NAGE) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ChromaDex Corp (NAGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.